TYBLUME Drug Patent Profile
✉ Email this page to a colleague
When do Tyblume patents expire, and when can generic versions of Tyblume launch?
Tyblume is a drug marketed by Exeltis Usa Inc and is included in one NDA.
The generic ingredient in TYBLUME is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for TYBLUME
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in TYBLUME? | TYBLUME excipients list |
| DailyMed Link: | TYBLUME at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TYBLUME
US Patents and Regulatory Information for TYBLUME
TYBLUME is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting TYBLUME
NEW DOSAGE FORM
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | TYBLUME | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 209405-001 | Mar 30, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
